A New Beacon For The Multiple Myeloma Community
There are probably few words more frightening than those of a doctor telling you “I’m sorry, but I’m afraid you have cancer.” Those words are even more frightening when you’re told the cancer you have...
View ArticleASH 2010 Multiple Myeloma Update – Day Two
Yesterday was the second full day of the 2010 American Society of Hematology annual meeting in Orlando. It was a particularly busy day in terms of material related to multiple myeloma, with numerous...
View ArticleASH 2010 Multiple Myeloma Update – Day Three Morning
Monday was the third full day of “ASH 2010,” this year’s annual meeting of the American Society of Hematology. This day was the busiest of the entire meeting in terms of multiple myeloma-related...
View ArticleASH 2010 Multiple Myeloma Update – Day Three Afternoon And Evening
This Monday was the third full day of the American Society of Hematology 2010 annual meeting, and it was packed with multiple myeloma-related presentations. The Beacon published an update earlier...
View ArticleASH 2011 Multiple Myeloma Update – Day One
Yesterday was the first day of the American Society of Hematology (ASH) 2011 annual meeting, which is being held in San Diego. Although the day featured no oral presentations of new myeloma-related...
View ArticleASH 2011 Multiple Myeloma Update – Day Two
Results from a number of multiple myeloma studies were presented yesterday during the second day of the American Society of Hematology (ASH) 2011 annual meeting in San Diego. Predicting Response To...
View ArticleASH 2011 Multiple Myeloma Update – Day Three Morning: Current Therapies
Yesterday, the third day of the American Society of Hematology (ASH) 2011 Annual Meeting in San Diego, was the busiest day of the meeting for people interested in multiple myeloma. Myeloma-related...
View ArticleASH 2011 Multiple Myeloma Update – Day Three Afternoon: Carfilzomib And...
The afternoon sessions of the third day of the American Society of Hematology (ASH) 2011 annual meeting in San Diego were just as awash with myeloma-related presentations as were the morning sessions....
View ArticleASH 2011 Multiple Myeloma Update – Day Four
On the fourth and final day of the American Society of Hematology (ASH) 2011 annual meeting, there was one session in the morning with a number of important myeloma-related presentations. The key...
View ArticleMultiple Myeloma And The ASH 2012 Meeting: Taking Stock And Tagging The...
This year’s meeting of the American Society of Hematology (ASH) was held December 8 through 11 in Atlanta. During the meeting, The Beacon published daily updates that provided overviews of the...
View ArticleClik here to view.
Kyprolis In Multiple Myeloma Patients With Kidney Damage
A new study provides the first detailed look at Kyprolis when it is used in multiple myeloma patients with kidney damage. The focus of the study is on determining how Kyprolis (carfilzomib) is...
View ArticleASCO 2013 And Multiple Myeloma: What Were The Highlights?
This year’s meeting of the American Society of Clinical Oncology (ASCO) was held May 31 through June 4 in Chicago. During the meeting, The Beacon published daily updates that provided overviews of the...
View ArticleClinical Trial To Test Fenofibrate (Tricor) As Anti-Myeloma Therapy
Researchers at the University of Miami’s Sylvester Cancer Center have started a Phase 2 clinical trial to test whether the cholesterol drug fenofibrate (Tricor) is effective, on its own, as an...
View Article
